Path ID: DB00289_MESH_D001289_1
Concepts
| Identifier | Name | Type |
|---|---|---|
| MESH:D000069445 | Atomoxetine | Drug |
| UniProt:P23975 | Sodium-dependent noradrenaline transporter | Protein |
| GO:0004972 | NMDA glutamate receptor activity | MolecularActivity |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| GO:0051620 | Noradrenaline uptake | BiologicalProcess |
| GO:0061535 | Glutamate secretion, neurotransmission | BiologicalProcess |
| MESH:D009638 | Noradrenaline | ChemicalSubstance |
| GO:0061533 | Norepinephrine secretion, neurotransmission | BiologicalProcess |
| MESH:D001289 | Attention deficit hyperactivity disorder | Disease |
Relationships
NOTE: predicates are annotated in Biolink Model (v1.3.0)
| Subject | Predicate | Object |
|---|---|---|
| Atomoxetine | DECREASES ACTIVITY OF | Sodium-Dependent Noradrenaline Transporter |
| Atomoxetine | DECREASES ACTIVITY OF | Nmda Glutamate Receptor Activity |
| Atomoxetine | POSITIVELY REGULATES | Dopamine Secretion, Neurotransmission |
| Sodium-Dependent Noradrenaline Transporter | PARTICIPATES IN | Noradrenaline Uptake |
| Nmda Glutamate Receptor Activity | PARTICIPATES IN | Glutamate Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | NEGATIVELY CORRELATED WITH | Attention Deficit Hyperactivity Disorder |
| Noradrenaline Uptake | DECREASES ABUNDANCE OF | Noradrenaline |
| Glutamate Secretion, Neurotransmission | CORRELATED WITH | Attention Deficit Hyperactivity Disorder |
| Noradrenaline | PARTICIPATES IN | Norepinephrine Secretion, Neurotransmission |
| Norepinephrine Secretion, Neurotransmission | NEGATIVELY CORRELATED WITH | Attention Deficit Hyperactivity Disorder |
Reference: